Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Maggi

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 13, 2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisFilippo Pietrantonio, Fausto Petrelli, Andrea Coinu, et al.
International Journal of Cancer|February 24, 2015
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumabValeria Musella, Filippo Pietrantonio, Eleonora Di Buduo, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesClaudio Vernieri, Monica Milano, Marta Brambilla, et al.
Plos One|April 3, 2014
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusFilippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
Medical Oncology (Northwood, London, England)|May 25, 2015
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastasesFilippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
International Journal of Molecular Sciences|September 6, 2013
Role of cMET in the development and progression of colorectal cancerJuan Carlos Samamé Pérez-Vargas, Pamela Biondani, Claudia Maggi, et al.
Italian Journal of Pediatrics|July 30, 2022
The COVID-related mental health load of neonatal healthcare professionals: a multicenter study in ItalyLuigi Gagliardi, Serena Grumi, Marzia Gentile, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|February 13, 2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisFilippo Pietrantonio, Fausto Petrelli, Andrea Coinu, et al.
International Journal of Cancer|February 24, 2015
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumabValeria Musella, Filippo Pietrantonio, Eleonora Di Buduo, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesClaudio Vernieri, Monica Milano, Marta Brambilla, et al.
Plos One|April 3, 2014
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusFilippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
Medical Oncology (Northwood, London, England)|May 25, 2015
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastasesFilippo Pietrantonio, Vincenzo Mazzaferro, Rosalba Miceli, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
International Journal of Molecular Sciences|September 6, 2013
Role of cMET in the development and progression of colorectal cancerJuan Carlos Samamé Pérez-Vargas, Pamela Biondani, Claudia Maggi, et al.
Italian Journal of Pediatrics|July 30, 2022
The COVID-related mental health load of neonatal healthcare professionals: a multicenter study in ItalyLuigi Gagliardi, Serena Grumi, Marzia Gentile, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
Pageof 4